TABLE OF CONTENTS
1 INTRODUCTION 57
1.1 OBJECTIVES OF THE STUDY 57
1.2 MARKET DEFINITION 57
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET 57
1.4 CURRENCY AND PRICING 59
1.5 LIMITATIONS 59
1.6 MARKETS COVERED 59
2 MARKET SEGMENTATION 62
2.1 MARKETS COVERED 62
2.2 GEOGRAPHICAL SCOPE 63
2.3 YEARS CONSIDERED FOR THE STUDY 64
2.4 DBMR TRIPOD DATA VALIDATION MODEL 65
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 68
2.6 MULTIVARIATE MODELING 69
2.7 COMPONENT LIFELINE CURVE 69
2.8 DBMR MARKET POSITION GRID 70
2.9 VENDOR SHARE ANALYSIS 71
2.10 MARKET APPLICATION COVERAGE GRID 72
2.11 SECONDARY SOURCES 73
2.12 ASSUMPTIONS 73
3 EXECUTIVE SUMMARY 74
3.1 PORTER'S FIVE FORCES MODEL 78
3.2 VALUE CHAIN ANALYSIS 79
3.3 REGULATORY STANDARDS 80
3.4 TECHNOLOGICAL TRENDS 81
3.5 BENEFITS OF DRUG MODELING SOFTWARE 82
4 MARKET OVERVIEW 83
4.1 DRIVERS 85
4.1.1 RISING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES 85
4.1.2 RISING DEMAND FOR NOVEL THERAPIES 87
4.1.3 PRECISION MEDICINE AND INTERVENTION OF AI IN DRUG MODELLING 88
4.2 RESTRAINTS 89
4.2.1 LACK OF QUALITY DATA BASE 89
4.2.2 HIGH COST OF MANUFACTURING OF DRUG MODELLING SOFTWARE 89
4.3 OPPORTUNITIES 90
4.3.1 CLOUD COMPUTING AND BIG DATA ANALYTICS IN DRUG MODELLING 90
4.3.2 INCREASING ADOPTION OF MODELLING TOOLS IN DRUG DISCOVERY 91
4.4 CHALLENGES 91
4.4.1 LACK OF PROCEDURE FOR MULTI-DRUG EFFECT ASSESMENT 91
4.4.2 CHALLENGES WITH MODEL INTERPRETATION 92
5 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY COMPONENTS 93
5.1 OVERVIEW 94
5.1.1 SOFTWARE 97
5.1.1.1 INTEGRATED 98
5.1.1.2 STANDALONE 98
5.1.1.3 LIGAND BASED 98
5.1.1.4 STRUCTURE BASED 98
5.2 SERVICES 98
5.2.1 PROFESSIONAL SERVICES 99
5.2.1.1 CONSULTING AND TRAINING 100
5.2.1.2 INTEGRATION AND IMPLEMENTATION 100
5.2.1.3 SUPPORT AND MAINTENANCE 100
5.2.2 MANAGED SERVICES 100
6 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM 101
6.1 OVERVIEW 102
6.2 WINDOWS 105
6.3 LINUX 105
6.4 MAC OS 106
6.5 OTHERS 107
7 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE 108
7.1 OVERVIEW 109
7.2 CLOUD BASED 112
7.3 HYBRID-BASED 112
7.4 ON-PREMISES 113
8 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE 114
8.1 OVERVIEW 115
8.2 LARGE ENTERPRISE SIZE 118
8.3 SMALL & MEDIUM ENTERPRISE SIZE 118
9 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY APPLICATION 120
9.1 OVERVIEW 121
9.2 GRAPHICAL MOLECULAR MODELING 124
9.3 GENE SEQUENCE ANALYSIS 124
9.4 PROTEIN MODELING 125
9.5 MODELING CRYSTAL STRUCTURES 126
9.6 CHEMINFORMATICS 127
9.7 HIGH THROUGHPUT VIRTUAL SCREENING 128
9.8 GAS & SOLUTION PHASE REACTION 128
9.9 MEDICAL IMAGING 129
9.10 OTHERS 130
10 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL 131
10.1 OVERVIEW 132
10.2 SUBSCRIPTION BASED 135
10.2.1 ANNUALLY SUBSCRIPTION 136
10.2.2 MONTHLY SUBSCRIPTION 136
10.3 ONE-TIME LICENSE 136
10.3.1 GROUP LICENSE 137
10.3.2 DESKTOP LICENSE 137
10.3.3 OTHERS 137
11 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY END USER 138
11.1 OVERVIEW 139
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 142
11.2.1 LARGE ENTERPRISE SIZE 143
11.2.2 SMALL & MEDIUM ENTERPRISE SIZE 143
11.3 CONTRACT RESEARCH ORGANIZATIONS 143
11.3.1 LARGE ENTERPRISE SIZE 144
11.3.2 SMALL & MEDIUM ENTERPRISE SIZE 144
11.4 RESEARCH INSTITUTES 144
11.4.1 LARGE ENTERPRISE SIZE 145
11.4.2 SMALL & MEDIUM ENTERPRISE SIZE 145
11.5 REGULATORY AUTHORITIES 145
11.5.1 LARGE ENTERPRISE SIZE 146
11.5.2 SMALL & MEDIUM ENTERPRISE SIZE 147
11.6 OTHERS 147
11.6.1 LARGE ENTERPRISE SIZE 148
11.6.2 SMALL & MEDIUM ENTERPRISE SIZE 148
12 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY REGION 149
12.1 MIDDLE EAST AND AFRICA 150
12.1.1 SOUTH AFRICA 160
12.1.2 SAUDI ARABIA 165
12.1.3 U.A.E. 170
12.1.4 EGYPT 175
12.1.5 ISRAEL 180
12.1.6 OMAN 185
12.1.7 BAHRAIN 190
12.1.8 KUWAIT 195
12.1.9 QATAR 200
12.1.10 REST OF MIDDLE EAST AND AFRICA 205
13 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: COMPANY LANDSCAPE 206
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 206
14 SWOT ANALYSIS 207
15 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, COMPANY PROFILE 208
15.1 DASSAULT SYSTEMES 208
15.1.1 COMPANY SNAPSHOT 208
15.1.2 REVENUE ANALYSIS 208
15.1.3 COMPANY SHARE ANALYSIS 209
15.1.4 PRODUCT PORTFOLIO 209
15.1.5 RECENT DEVELOPMENT 209
15.2 AMAZON WEB SERVICES, INC. OR ITS AFFILIATES.(A SUBSIDIARY OF AMAZON) 210
15.2.1 COMPANY SNAPSHOT 210
15.2.2 REVENUE ANALYSIS 210
15.2.3 COMPANY SHARE ANALYSIS 211
15.2.4 PRODUCT PORTFOLIO 211
15.2.5 RECENT DEVELOPMENTS 211
15.3 CERTARA, USA. 212
15.3.1 COMPANY SNAPSHOT 212
15.3.2 REVENUE ANALYSIS 212
15.3.3 COMPANY SHARE ANALYSIS 213
15.3.4 PRODUCT PORTFOLIO 213
15.3.5 RECENT DEVELOPMENTS 213
15.4 SCHRDINGER, INC. 214
15.4.1 COMPANY SNAPSHOT 214
15.4.2 REVENUE ANALYSIS 214
15.4.3 COMPANY SHARE ANALYSIS 215
15.4.4 PRODUCT PORTFOLIO 215
15.4.5 RECENT DEVELOPMENT 215
15.5 CRESSET. 216
15.5.1 COMPANY SNAPSHOT 216
15.5.2 COMPANY SHARE ANALYSIS 216
15.5.3 PRODUCT PORTFOLIO 217
15.5.4 RECENT DEVELOPMENTS 217
15.6 ACELLERA LTD 218
15.6.1 COMPANY SNAPSHOT 218
15.6.2 PRODUCT PORTFOLIO 218
15.6.3 RECENT DEVELOPMENTS 218
15.7 ARGUSLAB 219
15.7.1 COMPANY SNAPSHOT 219
15.7.2 PRODUCT PORTFOLIO 219
15.7.3 RECENT DEVELOPMENT 219
15.8 ATOMWISE INC. 220
15.8.1 COMPANY SNAPSHOT 220
15.8.2 PRODUCT PORTFOLIO 220
15.8.3 RECENT DEVELOPMENT 220
15.9 BC PLATFORMS 221
15.9.1 COMPANY SNAPSHOT 221
15.9.2 PRODUCT PORTFOLIO 221
15.9.3 RECENT DEVELOPMENTS 222
15.10 BIOSOLVEIT GMBH 223
15.10.1 COMPANY SNAPSHOT 223
15.10.2 PRODUCT PORTFOLIO 223
15.10.3 RECENT DEVELOPMENT 223
15.11 DOTMATICS 224
15.11.1 COMPANY SNAPSHOT 224
15.11.2 PRODUCT PORTFOLIO 224
15.11.3 RECENT DEVELOPMENTS 225
15.12 GENECODE 226
15.12.1 COMPANY SNAPSHOT 226
15.12.2 PRODUCT PORTFOLIO 226
15.12.3 RECENT DEVELOPMENT 226
15.13 INSILICOTRIALS TECHNOLOGIES. 227
15.13.1 COMPANY SNAPSHOT 227
15.13.2 PRODUCT PORTFOLIO 227
15.13.3 RECENT DEVELOPMENTS 228
15.14 NANOME INC. 229
15.14.1 COMPANY SNAPSHOT 229
15.14.2 PRODUCT PORTFOLIO 229
15.14.3 RECENT DEVELOPMENT 229
15.15 OPTIBRIUM, LTD. 230
15.15.1 COMPANY SNAPSHOT 230
15.15.2 PRODUCT PORTFOLIO 230
15.15.3 RECENT DEVELOPMENT 230
15.16 PHARMACELERA 231
15.16.1 COMPANY SNAPSHOT 231
15.16.2 PRODUCT PORTFOLIO 231
15.16.3 RECENT DEVELOPMENT 231
15.17 SIMULATIONS PLUS. 232
15.17.1 COMPANY SNAPSHOT 232
15.17.2 REVENUE ANALYSIS 233
15.17.3 COMPANY SHARE ANALYSIS 234
15.17.4 PRODUCT PORTFOLIO 234
15.17.5 RECENT DEVELOPMENT 235
15.18 THE SCRIPPS RESEARCH INSTITUTE 236
15.18.1 COMPANY SNAPSHOT 236
15.18.2 PRODUCT PORTFOLIO 236
15.18.3 RECENT DEVELOPMENT 236
15.19 VERISIM LIFE. 237
15.19.1 COMPANY SNAPSHOT 237
15.19.2 PRODUCT PORTFOLIO 237
15.19.3 RECENT DEVELOPMENTS 237
15.20 XTALPI INC. 238
15.20.1 COMPANY SNAPSHOT 238
15.20.2 PRODUCT PORTFOLIO 238
15.20.3 RECENT DEVELOPMENT 238
15.21 XYBION DIGITAL INC. 239
15.21.1 COMPANY SNAPSHOT 239
15.21.2 REVENUE ANALYSIS 239
15.21.3 PRODUCT PORTFOLIO 240
15.21.4 RECENT DEVELOPMENT 240
16 QUESTIONNAIRE 241
17 RELATED REPORTS 245

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.